Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndromes (LTS) by pharmacogenomic biomarkers.
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers / Bruera, G.; Massacese, S.; Pepe, F.; Malapelle, U.; Sayem, S.M. ABU SAYEM; Ciacco, E.; Calvisi, G.; Troncone, G.; Bosco, Simmaco; Ricevuto, E.. - In: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - ISSN 1758-8340. - 11:(2019), p. 1758835919846421. [10.1177/1758835919846421]
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
Malapelle U.Membro del Collaboration Group
;SAYEM, S.M. ABU SAYEMMembro del Collaboration Group
;Troncone G.Membro del Collaboration Group
;BOSCO, SIMMACOMembro del Collaboration Group
;
2019
Abstract
Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndromes (LTS) by pharmacogenomic biomarkers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
